This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alymova, I. V. Articles by McCullers, J. A. Search for Related Content PubMed PubMed Citation Articles by Alymova, I. V. Articles by McCullers, J. A.

The Novel Parainfluenza Virus Hemagglutinin-Neuraminidase Inhibitor BCX 2798 Prevents Lethal Synergism between a Paramyxovirus and Streptococcus pneumoniae

Department of Infectious Diseases,¹ Animal Resources Center, St. Jude Children's Research Hospital, Memphis, Tennessee,² BioCryst Pharmaceuticals, Inc., Birmingham, Alabama³

Received 12 April 2004/ Returned for modification 14 August 2004/ Accepted 22 September 2004

An association exists between respiratory viruses and bacterial infections. Prevention or treatment of the preceding viral infection is a logical goal for reducing this important cause of morbidity and mortality. The ability of the novel, selective parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 to prevent the synergism between a paramyxovirus and Streptococcus pneumoniae was examined in this study. A model of secondary bacterial pneumonia after infection with a recombinant Sendai virus whose hemagglutinin-neuraminidase gene was replaced with that of human parainfluenza virus type 1 [rSV(hHN)] was established in mice. Challenge of mice with a sublethal dose of S. pneumoniae 7 days after a sublethal infection with rSV(hHN) (synergistic group) caused 100% mortality. Bacterial infection preceding viral infection had no effect on survival. The mean bacterial titers in the synergistic group were significantly higher than in mice infected with bacteria only. The virus titers were similar in mice infected with rSV(hHN) alone and in dually infected mice. Intranasal administration of BCX 2798 at 10 mg/kg per day to the synergistic group of mice starting 4 h before virus infection protected 80% of animals from death. This effect was accompanied by a significant reduction in lung viral and bacterial titers. Treatment of mice 24 h after the rSV(hHN) infection showed no protection against synergistic lethality. Together, our results indicate that parainfluenza viruses can prime for secondary bacterial infections. Prophylaxis of parainfluenza virus infections with antivirals might be an effective strategy for prevention of secondary bacterial complications in humans.

This article has been cited by other articles:

• McCullers, J. A. (2006). Insights into the Interaction between Influenza Virus and Pneumococcus. Clin. Microbiol. Rev. 19: 571-582 [Abstract] [Full Text]  
• Avadhanula, V., Rodriguez, C. A., DeVincenzo, J. P., Wang, Y., Webby, R. J., Ulett, G. C., Adderson, E. E. (2006). Respiratory Viruses Augment the Adhesion of Bacterial Pathogens to Respiratory Epithelium in a Viral Species- and Cell Type-Dependent Manner. J. Virol. 80: 1629-1636 [Abstract] [Full Text]  
• Porotto, M., Fornabaio, M., Greengard, O., Murrell, M. T., Kellogg, G. E., Moscona, A. (2006). Paramyxovirus Receptor-Binding Molecules: Engagement of One Site on the Hemagglutinin-Neuraminidase Protein Modulates Activity at the Second Site. J. Virol. 80: 1204-1213 [Abstract] [Full Text]